Begoña Bermejo

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2022 · 365 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +7

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Antonio Llombart‐Cussac, Javier Cortés, Laia Paré et al. · The Lancet Oncology · 2017 · 329 citations

Breast Oncology, Medicine, Pathology +8

Spatial predictors of immunotherapy response in triple-negative breast cancer

Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang et al. · Nature · 2023 · 278 citations · Full text

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Aleix Prat, Giampaolo Bianchini, Marlène Thomas et al. · Clinical Cancer Research · 2014 · 232 citations

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Aleix Prat, Tomás Pascual, Carmine De Angelis et al. · JNCI Journal of the National Cancer Institute · 2019 · 163 citations · Full text